Deborah Dunsire, MD is the former President and CEO at FORUM Pharmaceuticals, a company that focused in therapies for Alzheimer’s disease and other dementias as well as therapies to improve cognition in Schizophrenia. Prior to joining the startup in 2013, she served as president and CEO of Millennium Pharmaceuticals from 2005 to 2013, during which time Takeda Pharmaceuticals of Japan acquired the company for $8.8 billion to build an oncology franchise. Following the acquisition, Deborah became the first woman to be appointed to the Japanese governing board of Takeda Pharmaceuticals. Prior to her role at Millenium, Deborah spent 17 years at Sandoz and Novartis and led the Novartis Oncology business in North America, launching a number of transformational cancer therapies.
Currently Deborah is vice-chair, and a trustee of the Museum of Science (Boston). She is a member of the Massachusetts General Hospital Research Advisory Council. She serves on the board of trustees for Northeastern University and sits on the Visiting Committee for the Department of Chemistry at MIT. She is a trustee for the Massachusetts General Physicians Organization.
Until its sale to Actavis in March of 2015, Deborah was a long standing board member of Allergan Pharmaceuticals and has also served for many years as a board member of the Biotechnology Innovation Organization.
Deborah was born in Zimbabwe and completed her medical training at the University of the Witwatersrand in South Africa.